Noubar Afeyan
Founder & CEO @ Flagship Pioneering
Cambridge, United States
Noubar Afeyan is a Series B investor at Flagship Pioneering in Cambridge focused on Biotechnology and Health Care. Noubar Afeyan is the Co-Founder of Etiome. He previously worked at Montai Health as a Co-Founder and Board Member. Noubar Afeyan attended the Massachusetts Institute of Technology.
- Total investments:
- 34
- Last investment:
- Lead investor:
- 74%
Last updated:
For AI agents: llms.txt
Industries Noubar Afeyan invests in
Stages Noubar Afeyan invests in
Countries Noubar Afeyan invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 19 (56%)
- Health Care 10 (29%)
- Medical 9 (26%)
- Therapeutics 7 (21%)
- Life Science 5 (15%)
Stage
- Series B 9 (26%)
- Series A 7 (21%)
- Series C 7 (21%)
- Funding Round 3 (9%)
- Venture - Series Unknown 3 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Serif Biomedicines is pioneering Modified DNA as a new type of biotechnology. Serif combines nucleic acid chemistry, synthetic biology, delivery technology, and artificial intelligence to develop programmable, scalable, long-lasting, and redosable DNA therapies. | $50M / Venture - Series Unknown / Apr 21, 2026 | ||
| Extuitive AI agents develop multiple product and ad versions and select the most effective concepts based on market trends. | $20M / Seed / Sep 18, 2025 | ||
| Terrana's innovative technological platform enables resilient agriculture in a fast changing world by providing RNA-based plant health solutions. | Jul 01, 2025 | ||
| Terrana's innovative technological platform enables resilient agriculture in a fast changing world by providing RNA-based plant health solutions. | $50M / Series B / Jul 01, 2025 | ||
| Prologue Medicines creates transformative medicines by systematically discovering and evaluating viral proteins and their unique features. | $50M / Series A / May 07, 2024 | ||
| Quotient Therapeutics engages in transformative medicines made possible with somatic genomics. | $50M / Seed / Nov 21, 2023 | ||
| Alltrna is the tRNA platform company to decipher tRNA biology and pioneer tRNA therapeutics to treat thousands of diseases. tRNAs play a central role in the translation of mRNA into proteins. tRNA biology modulates the complex code of DNA and RNA across translation and transcription. Altrna platform incorporates AI/ML tools to learn the tRNAlanguage and deliver diverse programmable molecules with broad therapeutic potential. | $109M / Series B / Aug 09, 2023 | ||
| Empress Therapeutics is a biotechnology business in its early stages focused on drug development and new molecular insights into health and illness. The company's proprietary bio platform uses evolution, human molecular and genetic data, and artificial intelligence to identify advanced starting points in endogenous drug-like molecules,allowing clinicians to treat a wide range of serious unmet medical needs with small-molecule drug candidates. | $50M / Venture - Series Unknown / Jun 21, 2023 | ||
| Metaphore Biotechnologies use biomimicry and machine learning to unveil the revolutionary medicinal potential of functional molecular mimics. The MIMiCTM platform, developed by the business, is a computationally driven bio platform for developing novel therapies in which function, specificity, and selectivity may be optimized. Metaphore isdedicated to uncovering previously inaccessible pharmacological targets and achieving breakthroughs that exceed today's medications for maximum patient effect. | $50M / May 16, 2023 | ||
| Cellarity's platform digitizes the molecular information in cells to elucidate how they behave in health and disease. Cellarity is using its platform to design medicines targeting the full cellular and molecular complexity of disease, enabling a quantum leap in the success rate and speed of drug discovery. | $121M / Series C / Oct 04, 2022 | ||
| See all 34 investments → | |||
Co-Investors
About Flagship Pioneering
Flagship Pioneering conceives, creates, resources, and grows first-in-category ventures to transform human health and sustainability. The company accelerates Flagship Pioneering’s advances in biology, engineering, medicine, energy, and beyond. The firm harnesses science and entrepreneurialism to envision alternative futures, beginning withseemingly unreasonable propositions and navigating to transformational outcomes through an evolutionary methodology.Flagship Pioneering combines innovative capacity, entrepreneurial leadership, and professional capital management in a single enterprise that systematically produces first-in-category companies.
Flagship Pioneering Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Geoffrey von Maltzahn
General Partner
|
|||
Hari Pujar
Operating Partner
|
|||
Paul Biondi
Executive Partner & President
|
|||
Thomas de Vlaam
Co-Founder FL86
|
|||
Avak Kahvejian
General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Noubar Afeyan invest in?
Noubar Afeyan invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series A stage. Most of the 34 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Noubar Afeyan?
Public channels for Noubar Afeyan include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Noubar Afeyan last invest?
The most recent investment recorded for Noubar Afeyan closed in Apr 2026. Shizune tracks 34 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
